Clinical trials: Septicemia
Toxic Shock Syndrome
Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Toxic Shock Syndrome (TSS) is a severe condition with high morbidity and mortality from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- NCT02814708
- Testing
- rTSST-1v
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Sepsis, Renal Failure
The Prevention of Failure to Rescue Using Early Warning Scoring
The purpose of this study is to assess if, compared with standard paper-based systems, an automated Early Warning System (EWS) resident in a spot check patient monitor, can help to identify deteriorating patients.
- Conditions
- Sepsis, Renal Failure, Pulmonary Edema, Cardio-pulmonary Arrest
- Trial name
- VitalCare (NCT01197326)
- Testing
- use of the MP5 EWS patient monitor
- Where
- Australia
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Philips Healthcare
Acute Respiratory Distress Syndrome, Sepsis
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
This study is a multi-center, randomized, partially double-blind, and placebo-controlled Phase Ib clinical trial of inhaled CO (iCO) for the treatment of sepsis-induced acute respiratory distress syndrome (ARDS).
- Trial name
- NCT04870125
- Testing
- Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- Brigham and Women's Hospital
Bacteremia, Fungemia
Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures
Would rapid identification of bacteria and rapid detection of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) (using an FDA-cleared assay) in positive blood culture bottles improve patient care…
- Conditions
- Bacteremia, Fungemia, Bloodstream Infection
- Trial name
- NCT01898208
- Testing
- FilmArray testing, Antimicrobial Stewardship, Bacterial culture
- Where
- United States
- Volunteers
- 743 people
- Sponsor
- Mayo Clinic
Gram-negative Bacteremia, Bloodstream Infection
Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial
This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive…
- Trial name
- FAST (NCT06174649)
- Testing
- Reveal
- Where
- 7 sites in Greece, India and 2 more
- Volunteers
- 899 people
- Sponsor
- Duke University
SIRS, Sepsis
Utility of Presepsin in Distinguishing Between Sepsis and SIRS
This is an observational study to evaluate the diagnostic accuracy of presepsin levels to discriminate between sepsis and SIRS upon presentation with critical illness compatible with either sepsis or systemic inflammatory…
- Trial name
- NCT02052895
- Where
- 2 sites in United States
- Volunteers
- 226 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Severe Sepsis
AZD9773 Dose Escalation Study
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773)…
- Trial name
- NCT00615017
- Testing
- AZD9773 (CytoFab)
- Where
- 26 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Clostridium Difficile Infection (CDI)
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
Administration of concomitant antibiotics (CA) is a known risk factor for treatment failure in the treatment of CDI, as well as for recurrence of CDI.
- Trial name
- NCT02692651
- Testing
- Fidaxomicin, Vancomycin
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- University of Michigan
Sepsis
Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
The rapidity and the quality of fluid resuscitation in patients with severe sepsis are important factors for the prevention of secondary multi-organ failure.
- Trial name
- CRYSTMAS (NCT00464204)
- Testing
- 6 % Hydroxyethylstarch 130/0.4 = "Voluven®", 0.9 % NaCl
- Where
- 24 sites in France, Germany
- Volunteers
- 196 people
- Sponsor
- Fresenius Kabi
Sepsis
Ubiquinol (Reduced COQ10) for Patients With Sepsis
This study aims to determine if Ubiquinol (reduced form of COQ10) will attenuate mitochondrial injury and decrease inflammatory response in patients suffering from sepsis.
- Trial name
- NCT01948063
- Testing
- Ubiquinol
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Beth Israel Deaconess Medical Center
Candidemia, Invasive Candidiases
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
This is a multicenter, open-label, single arm study to evaluate the efficacy and safety of APX001 for the treatment of candidemia and/or invasive candidiasis caused by C.
- Conditions
- Candidemia, Invasive Candidiases, Candida Infection
- Trial name
- APEX (NCT04148287)
- Testing
- APX001
- Where
- 2 sites in South Africa
- Volunteers
- 9 people
- Sponsor
- Basilea Pharmaceutica
Central Line-Associated Bloodstream Infection
Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Use of long-term central venous access devices (including tunneled lines and ports) can be associated with development of bloodstream infection caused by build-up of bacteria or fungus on the inside of the device, called central…
- Trial name
- NCT01472965
- Testing
- ethanol
- Where
- 2 sites in United States, Australia
- Volunteers
- 95 people
- Sponsor
- St. Jude Children's Research Hospital
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pediatric Sepsis-induced MODS
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
This study is an open-label, multi-center, interventional trial in which children with sepsis-induced MODS undergo surveillance immune function testing beginning on Day 2 of MODS.
- Trial name
- GRACE (NCT03769844)
- Testing
- GM-CSF
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Nationwide Children's Hospital
Sepsis, Infection
Paediatric Rapid Sepsis Trigger (PRST) Tool
Sepsis is the leading cause of death and disability in children, every hour of delay in treatment is associated with greater organ damage and ultimately death.
- Trial name
- PRST (NCT04304235)
- Testing
- Pediatric Rapid Sepsis Trigger (PRST) tool, Emergency Triage and Treatment (ETAT) guidelines
- Where
- 3 sites in Kenya, Uganda
- Volunteers
- 18,693 people
- Sponsor
- University of British Columbia
Central Line Associated Bloodstream Infections (CLABSI), Bone Marrow Transplant
Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT
The purpose of this study is to see if applying parafilm as an external barrier on the central line in children having a bone marrow transplant helps to prevent central line associated bloodstream infection(s) and also to assess…
- Trial name
- NCT02575079
- Testing
- Parafilm
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Emory University
Sepsis
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis.
- Trial name
- NCT00089986
- Testing
- Intravenous GR270773- Phospholipid Emulsion
- Where
- 390 sites in United States, Argentina and 32 more
- Volunteers
- 1,415 people
- Sponsor
- GlaxoSmithKline
Bacterial Infection, Benign Neoplasm
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
This randomized phase III trial studies chlorhexidine gluconate cleansing to see how well it works compared to control cleansing in preventing central line associated bloodstream infection and acquisition of multi-drug resistant…
- Conditions
- Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection
- Trial name
- NCT01817075
- Testing
- Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser
- Where
- 59 sites in United States, Canada and 1 more
- Volunteers
- 177 people
- Sponsor
- Children's Oncology Group
Acute Kidney Injury
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).
- Trial name
- NCT01400893
- Testing
- SCD
- Where
- 26 sites in United States
- Volunteers
- 134 people
- Sponsor
- SeaStar Medical
Muscle Weakness, Sepsis
Evaluating Muscle Weakness Improvement With Lorcaserin in ICU
ICU acquired muscle weakness is a significant problem in patients recovering from critical illness. This trial will evaluate the safety and efficacy of a drug in improving muscle weakness in critically ill patients.
- Trial name
- EMILI (NCT02523690)
- Testing
- Lorcaserin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University